Priveterra Acquisition Corporation (PMGM) Adjourns Completion Vote for Seventh Time
by Marlena Haddad on 2023-06-28 at 5:16pm

Priveterra Acquisition Corp. (NASDAQ:PMGM) announced this afternoon that its special meeting, intended to approve its combination with AEON Biopharma, has been adjourned for the seventh consecutive time.

Given the SPAC’s completion deadline of August 11, it is unlikely that this will be the last adjournment we will see for this completion vote.

Initially scheduled for noon today, the meeting has now been pushed back until June 30 at 4:00 p.m. Priveterra continues to reiterate its commitment to utilizing the extended time during the postponement to further engage with its shareholders.

The deal with AEON Biopharma includes a $40 million minimum cash condition, half of which has already been secured through a $20 million commitment from existing AEON investors at $7 per share. But, Priveterra’s trust, originally totaling $276 million, has been reduced to about $20.3 million after seeing 92.7% of shares redeemed in earlier votes.

Priveterra inked its $201.8 million business combination with drug developer AEON on December 13. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.

 

Recent Posts
by Kristi Marvin on 2024-10-26 at 10:00am

Terms Tracker for the Week Ending October 25, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Finally, a little more SPAC action this week with no less than four IPOs priced.  That brings October’s tally to seven IPOs with one more...

by Nicholas Alan Clayton on 2024-10-25 at 8:15am

At the SPAC of Dawn The rebound of the growth companies that made up the SPAC class of 2021 has been one of the bigger stories of second half of 2024, but not all of the de-SPACs are feeling the love equally. Instead, in many new sectors that hit the public markets together as a...

by Nicholas Alan Clayton on 2024-10-24 at 11:54am

DT Cloud (NASDAQ:DYCQ) has entered into a definitive agreement to combine with Maius Pharmaceutical at an equity value of $250 million. Shanghai-based Maius is a drug developer and researcher focused on small-molecule chemical treatments for different forms of cancer. The combined company is expected to trade on the Nasdaq once the deal is completed in...

by Nicholas Alan Clayton on 2024-10-24 at 10:18am

Charlton Aria Acquisition Corporation announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CHARU”, Thursday, October 24, 2024. The new SPAC plans to focus on industries that complement the management team’s and board of director’s background and network. The sponsor team for...

by Nicholas Alan Clayton on 2024-10-24 at 8:30am

At the SPAC of Dawn As the market goes through a cooling period this week, new readouts for jobless claims and new home sales are set to hit later today. Jobless claims are of course something of a proxy indicator for SPACs as to when the Fed might continue to its rate-cutting process, while home...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved